BofA raised the firm’s price target on Ocular Therapeutix (OCUL) to $21 from $18 and keeps a Buy rating on the shares. The firm hosted CEO Pravin Dugel to discuss key upcoming catalysts and he emphasized Axpaxli’s development plan supported by the pivotal studies in wet age-related macular degeneration and in diabetic retinopathy, the analyst tells investors. The firm, which remains “bullish” on Axpaxli’s differentiated value proposition in wAMD and the potential for accelerated timelines, notes that the CEO expressed “high confidence” ahead of the SOL-1 trial readout.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’
- Buy Rating for Ocular Therapeutix: Accelerated Axpaxli Launch and FDA Engagement Drive Positive Outlook
- Accelerated Market Entry for Axpaxli Boosts Ocular Therapeutix’s Competitive Edge: Buy Rating Justified
- Ocular Therapeutix up 13% at $14.22 on accelerated AXPAXLI NDA submission plans
- Ocular announces plans to accelerate AXPAXLI NDA submission timeline